What is Agios Pharmaceuticals's gross unrealized gains?

Agios Pharmaceuticals (AGIO) reported gross unrealized gains of $723K in Q1 2026.

How has Agios Pharmaceuticals's gross unrealized gains changed year-over-year?

Agios Pharmaceuticals's gross unrealized gains decreased by 44.3% year-over-year, from $1.3M to $723K.

What is the long-term trend for Agios Pharmaceuticals's gross unrealized gains?

Over 5 years (2020 to 2025), Agios Pharmaceuticals's gross unrealized gains has grown at a 47.7% compound annual growth rate (CAGR), from $321K to $2.25M.

Agios Pharmaceuticals AGIO Gross Unrealized Gains

Gross Unrealized Gains at other companies

BioMarin PharmaceuticalsBMRN

——

PrecigenPGEN

——

BioCryst PharmaceuticalsBCRX

——

BridgeBio PharmaBBIO

——

Ligand PharmaceuticalsLGND

——

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$20.7M+138%

Gross profit$19.4M+154%

Operating income-$110.0M-3.2%

Net income-$99.1M-11.0%

EPS (diluted)-$1.69-9.0%

Balance sheet

See full

Cash & equivalents$113.6M+43.9%

Total debt$35.7M-32.5%

Total equity$1.1B-24.4%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow-$118.9M-6.7%

CapEx$769.0K+0.4%

Free cash flow-$119.7M-6.6%

Valuation

See full

Market cap$2.12B+18.1%

Enterprise value$2.04B+15.2%

P/S32.1×-16.4×

Profitability

See full

Gross margin90%+2.5pp

Operating margin-720%-204pp

Net margin-639.8%—

FCF margin-582.5%-185pp

Returns & leverage

See full

Return on equity-32.8%—

Debt / equity0×0.0×

Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's gross unrealized gains.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Agios Pharmaceuticals's gross unrealized gains?: Agios Pharmaceuticals (AGIO) reported gross unrealized gains of $723K in Q1 2026.
How has Agios Pharmaceuticals's gross unrealized gains changed year-over-year?: Agios Pharmaceuticals's gross unrealized gains decreased by 44.3% year-over-year, from $1.3M to $723K.
What is the long-term trend for Agios Pharmaceuticals's gross unrealized gains?: Over 5 years (2020 to 2025), Agios Pharmaceuticals's gross unrealized gains has grown at a 47.7% compound annual growth rate (CAGR), from $321K to $2.25M.